Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1+
SponsorCentre Hospitalier Universitaire, Amiens
About this trial
Current diagnostic methods rely primarily on clinical symptoms, supplemented by brain imaging and physiological tests. However, these signs of injury only become apparent once significant damage has occurred, thus delaying intervention and compromising the effectiveness of treatments. Therefore, there is a need to develop new markers to develop preventive measures for the consequences of perinatal asphyxia.
The primary objective is to compare cognitive and motor development at 18 months in three populations (PA, at risk of PA, and Control) defined on the basis of clinical, biological, and neural criteria.
Eligibility criteria
Qualifiers
Full-term infants (born between 36 and 42 weeks of gestation), clinically "normal" and without PA. Infants must have birth weights within the normal range for their gestational age.
Satisfactory Apgar scores at 1, 3, and 5 minutes, indicating good health.
Meet specific biochemical biomarker criteria as defined by the study protocols.
No major complications should occur during pregnancy or delivery.
Disqualifiers
Full-term newborn not meeting inclusion criteria
Trial design
Treatments tested in this trial
- EEG
Treatment groups
280 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov